Clinical commentary: Reaching new targets in monotherapy and combination therapy
1Baylor College of Medicine, Center for Cardiovascular Disease Prevention, 6565 Fannin, Suite B-160, Houston, TX 77030, USA.
Insights
New guidelines recommend lower LDL cholesterol goals, increasing the need for effective lipid-lowering therapies. This review explores statin-sparing options and cholesterol absorption inhibitors for managing cardiovascular risk factors.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Cardiovascular disease is the leading cause of death in the U.S.
- Declining coronary heart disease death rates may stem from aggressive risk factor management.
- Updated guidelines lower low-density lipoprotein cholesterol (LDL-C) targets for high-risk individuals.
Purpose of the Study:
- To review effective lipid-lowering therapies beyond statins.
- To discuss statin-sparing combination therapies.
- To explore the role of cholesterol absorption inhibitors.
Main Methods:
- Literature review of lipid-lowering strategies.
- Analysis of current treatment guidelines.
- Discussion of therapeutic options for statin-intolerant patients.
Main Results:
- Statin-based therapies are primary treatments for dyslipidemia.
- Increased statin use leads to higher rates of statin intolerance.
- Statin-sparing combinations and cholesterol absorption inhibitors offer alternative treatment options.
Conclusions:
- More efficacious lipid-lowering therapies are needed to meet new LDL-C goals.
- Statin-sparing regimens are crucial for managing high-risk patients.
- Cholesterol absorption inhibitors present a viable option for combination therapy.
Abstract:
Cardiovascular disease remains the most common cause of death in the United States. There has, however, been a decline in the age-adjusted death rate for coronary heart disease. This decline may be due, in part, to more aggressive treatment guidelines for treating cardiovascular risk factors, such as hypertension, diabetes, and dyslipidemia. The 2004 update to the National Cholesterol Education Program guidelines have recommended lower low-density lipoprotein cholesterol goals in high-risk patients. Based on the new targets for low-density lipoprotein cholesterol, clinicians will need more efficacious lipid-lowering therapies and improved options for combination therapy. Statin and statin-based combinations have been the mainstays of therapy during the last several years, and as statin utilization increases in the United States, more high-risk patients become exposed to potential statin intolerance. This commentary reviews statin-sparing combinations and use of cholesterol-absorption inhibitors.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers